Job ID: 2017-0224
Job date: 2017-02-25
End Date:
Company : Foundation Medicine Country : Role : Research Scientist
Job date: 2017-02-25
End Date:
Company : Foundation Medicine Country : Role : Research Scientist
Job Description:
The Bioinformatics Scientist will be responsible for development of clinical diagnostic assays and biomarker signatures for pharmaceutical partners through research, implementation, and validation of advanced computational methods. The successful candidate will possess strong analytical skills, solid programming experience, a high level of professional maturity, and ability to consistently meet deadlines under pressure. Responsibilities: Your impact on the Patient Journey As a member of the Penzberg team, you will be responsible for: -Development, analysis and testing of advanced computational methods to enhance FM’s clinical diagnostic platform with an emphasis on rigorously validated results and robust procedures to bring methods to the operational level. -Delivery of novel biomarker signatures based on NGS to pharmaceutical partners and academic collaborators, with an emphasis on accuracy and timeliness. -Development and validation of clinical diagnostic assays for pharmaceutical partners based on massively parallel sequencing (NGS) data. -Assuming responsibility for developing annotated genomic profiles of somatic aberrations based on NGS, in the context of studies of cancer-patient samples. -Collaborating with other technical teams in specifying requirements for tools to enhance workflow efficiency and robustness. -Assisting with drafting and completing manuscripts for publication; manage data analysis and interpretation of study results throughout manuscript publication process from draft through submission and acceptance. Qualifications: Your Expertise -Either PhD or MS in Bioinformatics, Computer Science, or a related field with a significant quantitative base. For MS, requires 3+ years’ experience in the biopharmaceutical/diagnostics industry or similar academia research. -Possess extensive scientific understanding of cancer genetics and genomics and show a strong capacity for independent thinking. -Track record of achievement in developing computational biology methods. -Highly desirable experience in software engineering, writing production level code with rigorous testing. -Working knowledge of cancer genetics and experience with Next-Generation Sequencing (NGS) -Experience with bioinformatics tools and databases. -Familiar with UNIX environment and use of clusters to parallelize the execution of computational methods. -Experience working within a CLIA certified clinical diagnostics laboratory. -Confident, proactive individual capable of taking the initiative and driving to results. -Strong organizational skills in order to maintain a high level of productivity innovation, and setting priorities in order to complete assignments in a timely manner. -Fluency in English is required. -A high level of professional maturity, including an ability to consistently meet tight deadlines under pressure and command attention and respect in a client-facing setting. -Capability of highly-independent work as well as being a team player and role model. -High energy level, a driving sense of urgency and a seasoned “make it happen/can do” orientation
Additional Info:
Foundation Medicine is leading a transformation in cancer care, where each patient’s treatment is informed by a deep understanding of the molecular changes that contribute to their disease. As a molecular information company, we are focused on fundamentally changing the way in which patients with cancer are treated. Our products provide more than information. They offer hope to patients, their families and friends, their physicians and caregivers. In 2015, Roche and Cambridge, MA-based Foundation Medicine announced a broad, strategic collaboration in the field of molecular information for oncology. The collaboration is a multi-part agreement that includes an R&D collaboration, a U.S. educational support collaboration, and an ex-U.S. commercial collaboration, among other aspects. Roche also invested $250 million into Foundation Medicine and, as part of a stock purchase, became a majority shareholder in Foundation Medicine. We believe this strategic collaboration accelerates and strengthens our respective leadership positions delivering molecular information solutions globally and advancing precision medicine in oncology. As part of the commercial collaboration, Foundation Medicine is building and plans to operate a molecular information, next generation sequencing facility in Penzberg, Germany. This laboratory will serve as Foundation Medicine’s strategic hub for commercial growth in several countries in Europe. As such, Foundation Medicine is actively recruiting for a at its Penzberg, Germany site. What makes Foundation Medicine so special? The cancer treatment paradigm is evolving rapidly and we believe there is now widespread recognition that cancer is a disease of the genome, rather than a disease defined solely by its specific anatomical location in the body. Today, physicians increasingly use precision medicines to target cancers based on the specific genomic alterations driving their growth, but most currently available molecular diagnostic tests only reveal a few of the possible alterations. Foundation Medicine provides truly comprehensive molecular information products that can assess the broadest range of relevant genomic alterations from a patient’s tumor and distill this complex molecular information into a concise and actionable format that reveals more treatment options for physicians and their patients. We've seen the difference that our technology can make in the lives of patients, but there is still enormous potential to help even more people. In our drive to help transform the way in which patients with cancer are treated, we strive to improve every life we touch through our dedication to innovation, our commitment to people, and our passion for performance.[Click Here to Access the Original Job Post]
The Bioinformatics Scientist will be responsible for development of clinical diagnostic assays and biomarker signatures for pharmaceutical partners through research, implementation, and validation of advanced computational methods. The successful candidate will possess strong analytical skills, solid programming experience, a high level of professional maturity, and ability to consistently meet deadlines under pressure. Responsibilities: Your impact on the Patient Journey As a member of the Penzberg team, you will be responsible for: -Development, analysis and testing of advanced computational methods to enhance FM’s clinical diagnostic platform with an emphasis on rigorously validated results and robust procedures to bring methods to the operational level. -Delivery of novel biomarker signatures based on NGS to pharmaceutical partners and academic collaborators, with an emphasis on accuracy and timeliness. -Development and validation of clinical diagnostic assays for pharmaceutical partners based on massively parallel sequencing (NGS) data. -Assuming responsibility for developing annotated genomic profiles of somatic aberrations based on NGS, in the context of studies of cancer-patient samples. -Collaborating with other technical teams in specifying requirements for tools to enhance workflow efficiency and robustness. -Assisting with drafting and completing manuscripts for publication; manage data analysis and interpretation of study results throughout manuscript publication process from draft through submission and acceptance. Qualifications: Your Expertise -Either PhD or MS in Bioinformatics, Computer Science, or a related field with a significant quantitative base. For MS, requires 3+ years’ experience in the biopharmaceutical/diagnostics industry or similar academia research. -Possess extensive scientific understanding of cancer genetics and genomics and show a strong capacity for independent thinking. -Track record of achievement in developing computational biology methods. -Highly desirable experience in software engineering, writing production level code with rigorous testing. -Working knowledge of cancer genetics and experience with Next-Generation Sequencing (NGS) -Experience with bioinformatics tools and databases. -Familiar with UNIX environment and use of clusters to parallelize the execution of computational methods. -Experience working within a CLIA certified clinical diagnostics laboratory. -Confident, proactive individual capable of taking the initiative and driving to results. -Strong organizational skills in order to maintain a high level of productivity innovation, and setting priorities in order to complete assignments in a timely manner. -Fluency in English is required. -A high level of professional maturity, including an ability to consistently meet tight deadlines under pressure and command attention and respect in a client-facing setting. -Capability of highly-independent work as well as being a team player and role model. -High energy level, a driving sense of urgency and a seasoned “make it happen/can do” orientation
Requeriments :
Skills :
- Biomarker Discovery
- Cancer biology
- Genetics
- genomic
- Lunix/Unix
- Next Generation Sequencing
- Programing Skills
- Software Design
Areas :
Additional Info:
Foundation Medicine is leading a transformation in cancer care, where each patient’s treatment is informed by a deep understanding of the molecular changes that contribute to their disease. As a molecular information company, we are focused on fundamentally changing the way in which patients with cancer are treated. Our products provide more than information. They offer hope to patients, their families and friends, their physicians and caregivers. In 2015, Roche and Cambridge, MA-based Foundation Medicine announced a broad, strategic collaboration in the field of molecular information for oncology. The collaboration is a multi-part agreement that includes an R&D collaboration, a U.S. educational support collaboration, and an ex-U.S. commercial collaboration, among other aspects. Roche also invested $250 million into Foundation Medicine and, as part of a stock purchase, became a majority shareholder in Foundation Medicine. We believe this strategic collaboration accelerates and strengthens our respective leadership positions delivering molecular information solutions globally and advancing precision medicine in oncology. As part of the commercial collaboration, Foundation Medicine is building and plans to operate a molecular information, next generation sequencing facility in Penzberg, Germany. This laboratory will serve as Foundation Medicine’s strategic hub for commercial growth in several countries in Europe. As such, Foundation Medicine is actively recruiting for a at its Penzberg, Germany site. What makes Foundation Medicine so special? The cancer treatment paradigm is evolving rapidly and we believe there is now widespread recognition that cancer is a disease of the genome, rather than a disease defined solely by its specific anatomical location in the body. Today, physicians increasingly use precision medicines to target cancers based on the specific genomic alterations driving their growth, but most currently available molecular diagnostic tests only reveal a few of the possible alterations. Foundation Medicine provides truly comprehensive molecular information products that can assess the broadest range of relevant genomic alterations from a patient’s tumor and distill this complex molecular information into a concise and actionable format that reveals more treatment options for physicians and their patients. We've seen the difference that our technology can make in the lives of patients, but there is still enormous potential to help even more people. In our drive to help transform the way in which patients with cancer are treated, we strive to improve every life we touch through our dedication to innovation, our commitment to people, and our passion for performance.[Click Here to Access the Original Job Post]